A phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of apremilast (CC-10004) in subjects with moderate to severe atopic dermatitis

Trial Profile

A phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of apremilast (CC-10004) in subjects with moderate to severe atopic dermatitis

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Apremilast (Primary)
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 05 Apr 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Jan 2016 According to a Celgene Corporation media release, data from this trial is expected in 2016.
    • 23 Jul 2015 Status changed from recruiting to active, no longer recruiting, as per Celgene corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top